These findings suggest that HER2+ BC patients, particularly those with advanced disease and resistance to HER2-targeted therapies, may benefit from the addition of PI3K/AKT inhibitors during neoadjuvant or adjuvant treatment phases. Here, AKT1 is linked to breast cancer.